Experts Discuss the RCC Landscape and Available Therapy for Patients

Factors Influencing Frontline Therapy Options for Favorable-Risk RCC

January 9th 2023

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.

Current and Potential Second-Line Therapies Following IO/TKI in RCC

ByBradley McGregor, MD

November 11th 2022

Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.

Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCC

ByManojkumar Bupathi, MD, MS

October 17th 2022

Manojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.

Ongoing Trials Investigate Intensified Frontline Therapy for RCC

ByBradley McGregor, MD

September 26th 2022

Bradley A. McGregor, MD, discusses new trials of intensified combination regimens for frontline treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma.

Recommendations for Treating Non–Clear Cell RCC

ByPedro C. Barata, MD, MSc

August 19th 2022

Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.

Key Considerations for Selecting Frontline Therapy in Advanced RCC

ByNaomi Haas, MD

June 24th 2022

Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.